{"entity":{"id":"nct07819136","kind":"trial","name":"REC-7735 in Participants With Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of REC-7735 run by Recursion Pharmaceuticals Inc., now recruiting.","summary":"REC-7735 in Participants With Solid Tumors is a phase 1/2 interventional study registered as NCT07819136 by Recursion Pharmaceuticals Inc., with 90 participants planned, started 2026-09. Conditions recorded: Solid Tumors. Interventions recorded: REC-7735.","status":"recruiting","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT07819136","url":"https://clinicaltrials.gov/study/NCT07819136"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["rec-7735"],"companies":["recursion"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07819136","phase":"1/2","setting":"A Phase 1 / 2, Open-Label Study of REC-7735 in Participants With Unresectable, Locally Advanced, or Metastatic PIK3CA-H1047R Mutated Solid Tumors","sponsor":"Recursion Pharmaceuticals Inc.","enrolled":90,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07819136/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"rec-7735","kind":"drug","name":"REC-7735","route":"/drugs/rec-7735/"}],"company":[{"id":"recursion","kind":"company","name":"Recursion Pharmaceuticals","route":"/companies/recursion/"}]}}